Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller
{"title":"2015年至2021年美国儿童牛皮癣全身治疗的患病率和趋势","authors":"Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller","doi":"10.1007/s13555-025-01545-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.</p><p><strong>Methods: </strong>In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan<sup>®</sup> database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.</p><p><strong>Results: </strong>A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).</p><p><strong>Conclusions: </strong>In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.\",\"authors\":\"Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller\",\"doi\":\"10.1007/s13555-025-01545-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.</p><p><strong>Methods: </strong>In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan<sup>®</sup> database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.</p><p><strong>Results: </strong>A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).</p><p><strong>Conclusions: </strong>In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01545-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01545-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.
Introduction: Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.
Methods: In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan® database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.
Results: A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).
Conclusions: In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
